Ratings for Veeva Systems VEEV were provided by 20 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 10 | 3 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 1 | 1 | 0 |
| 2M Ago | 4 | 5 | 2 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $243.5, along with a high estimate of $270.00 and a low estimate of $203.00. This current average reflects an increase of 11.19% from the previous average price target of $219.00.
Decoding Analyst Ratings: A Detailed Look
The perception of Veeva Systems by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Rishi Jaluria | RBC Capital | Maintains | Outperform | $250.00 | - |
| Brian Peterson | Raymond James | Maintains | Outperform | $260.00 | $260.00 |
| Anne Samuel | JP Morgan | Raises | Neutral | $222.00 | $183.00 |
| Craig Hettenbach | Morgan Stanley | Raises | Underweight | $210.00 | $160.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $250.00 | $232.00 |
| David Windley | Jefferies | Raises | Buy | $270.00 | $225.00 |
| Joe Vruwink | Baird | Raises | Outperform | $251.00 | $245.00 |
| Tyler Radke | Citigroup | Raises | Buy | $264.00 | $240.00 |
| Gabriela Borges | Goldman Sachs | Raises | Buy | $248.00 | $219.00 |
| David Grossman | Stifel | Raises | Buy | $250.00 | $205.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $203.00 | $187.00 |
| Ryan MacDonald | Needham | Raises | Buy | $260.00 | $220.00 |
| Saket Kalia | Barclays | Raises | Overweight | $245.00 | $240.00 |
| Brent Bracelin | Piper Sandler | Raises | Overweight | $245.00 | $220.00 |
| Karl Keirstead | UBS | Raises | Neutral | $235.00 | $185.00 |
| Saket Kalia | Barclays | Raises | Overweight | $240.00 | $220.00 |
| Ken Wong | Oppenheimer | Maintains | Outperform | $225.00 | $225.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $232.00 | $210.00 |
| Rishi Jaluria | RBC Capital | Raises | Outperform | $250.00 | $225.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Veeva Systems compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Veeva Systems's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Veeva Systems's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Veeva Systems analyst ratings.
Unveiling the Story Behind Veeva Systems
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
A Deep Dive into Veeva Systems's Financials
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Veeva Systems showcased positive performance, achieving a revenue growth rate of 11.93% as of 31 January, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 23.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veeva Systems's ROA excels beyond industry benchmarks, reaching 2.65%. This signifies efficient management of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
